Section Arrow
CGEM.NASDAQ
- Cullinan Therapeutics
Quotes are at least 15-min delayed:2026/09/03 01:29 EDT
Regular Hours
Last
 22.33
+0.54 (+2.48%)
Day High 
22.79 
Prev. Close
21.79 
1-M High
23.19 
Volume 
769.69K 
Bid
18.5
Ask
23.2
Day Low
21.75 
Open
21.88 
1-M Low
16.02 
Market Cap 
1.40B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 22.14 
20-SMA 20.68 
50-SMA 18.87 
52-W High 23.19 
52-W Low 5.68 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.11/-3.17
Enterprise Value
1.40B
Balance Sheet
Book Value Per Share
5.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PPBTPurple Biotech Ltd.1.98+0.32+19.28%0PE
GERNGeron Corp1.59+0.11+7.43%-- 
CANFCan-Fite Biopharma Ltd2.36-0.93-28.27%-- 
MRNAModerna150.81-3.46-2.24%-- 
RXRXRecursion Pharmaceuticals3.38+0.05+1.50%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.